SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals more than 18,000, including physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from 76 countries around the world.
SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals over 18,000, which includes physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from more than 75 countries around the world. SNMMI's Journal of Nuclear Medicine (JNM), the premier international journal of nuclear medicine, reaches over 18,000 individuals each month. SNMMI's Annual Meeting is nuclear medicine's and molecular iamging's largest gathering each year, attracting over 4,000 professional attendees and another 2,500 industry representatives.
At the most recent Annual Meeting in June 2013 in Vancouver, BC, Canada, 38% of registered attendees were from countries other than the United States. Attendees represented over 69 countries. In addition, abstract submissions for SNMMI's Annual Meeting from outside the United States represent close to 65% of all submissions.
While SNMMI's headquarters office resides in Virginia, just outside of Washington, D.C., its perspective, programs, and growth are as international as its members. As of 2013, more than 11.8% of the Society's members reside in more than 75 countries other than the United States.
Search for an international nuclear medicine and molecular imaging organization near you.
SNMMI's educational programs and activities reflect the increasing importance and participation of its international members. Such common global nuclear medicine and molecular imaging and therapy issues as quality of care, educating referring physicians and patients, and exploring ways to better share developments in the practice of nuclear medicine and molecular imaging and therapy are but a few of the activities currently underway by Society staff, Committees, Councils, and our Centers of Excellence. This website seeks to constantly expand its offerings to the Society's international members, providing an ever-changing, updated array of global resources and news for nuclear medicine and molecular imaging and therapy professionals literally anywhere on the globe.
SNMMI continues to stay actively involved in several jointly sponsored educational programs and educational outreach activities with regional nuclear medicine and molecular imaging and therapy organizations around the world; both in their home countries, and during SNMMI's Annual Meeting. These joint sponsored programs include not only the sharing of speakers and renown experts on all facets of nuclear medicine and molecular imaging, collaboration on the development of enduring educational materials, and programmatic/administrative support, but also include translation of materials and website development.
Each year, the SNMMI collaborates with international organizations in an effort to continue the exchange of ideas, education and knowledge. Intiatives include:
Nuclear Medicine Global Initiative
3rd Sino-American Conference
Chinese/U.S. Resident Exchange Program
IAEA CT Case Webinar Series
EANM Collaborative Guidelines
Make your plans to attend the SNMMI 2015 Annual Meeting, June 6-10 in Baltimore, Maryland.
This year's Annual Meeting features more than 150 scientific and CE sessions, covering the latest advances in the profession.
SNMMI offers a Full International Membership category for inernational colleagues. Learn more on how to become an SNMMI Full Member (international).
Available to physicians, scientists or pharmacists possessing an advanced degree who have presented credentials indicating their professional activity, either, medical, paramedical, investigational or educational in the scientific or clinical disciplines of molecular imaging or nuclear medicine. This includes the diagnostic, therapeutic or investigational use of radionuclides or other molecular imaging technologies.
Annual dues: $460
Includes subscription to The Journal of Nuclear Medicine.
Includes voting rights and can be elected an Officer of the SNMMI.
As part of its continuing commitment to growing the practice of nuclear medicine and molecular imaging and therapy worldwide, SNMMI leadership works diligently to develop strategic alliances with key regional nuclear medicine organizations to assist these groups in expanding the scope and quality of nuclear medicine outside the United States. These strategic alliances stretch across the globe. reaching every continent where SNMMI's members reside and practice.
SNMMI Partners and Alliances Include:
For more information on SNMMI's international activities and programs, please contact:
Nikki Wenzel-Lamb, MBA Director of Leadership Direct: 703-652-6766 Fax: 703-708-9020 Email: email@example.com
The National Cancer Institute’s SBIR Development Center recently announced new contract funding opportunities in a range of novel technology areas including molecularly targeted radiation therapy (TRT) for cancer treatment.
Whole-body metabolic tumor volume, as determined by FDG-PET/CT before treatment, is a reliable prognosticator of overall survival in patients who have invasive ductal carcinoma (IDC) of the breast and distant metastases at the time of their initial diagnosis, according to a study published online July 23 in the American Journal of Roentgenology.
(MI: Making a Difference)
A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
(MI: Making a Difference)
Results from the randomized intergroup European Organisation for Research and Treatment of Cancer, Lymphoma Study Association and Fondazione Italiana Linfomi H10 trial have demonstrated that early FDG-PET adapted treatment improves outcomes of early FDG-PET-positive patients with stage I/II Hodgkin’s lymphoma (HL).
(MI: Making a Difference)
More than 60 countries are represented each year among the scientific abstracts featured at SNMMI's Annual Meeting. For the first time, SNMMI will recognize the best scientific abstract from each submitting country.
This reception will bring together the winner from each country along with the Leadership of the Society to celebrate the extraordinary work that is being done around the globe to further the effectiveness of nuclear medicine and molecular imaging and ultimately to contribute to better diagnosis and treatment for patients.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.